3.35 -0.04 (-1.27%)
After hours: 4:11PM EST
|Bid||3.35 x 300|
|Ask||3.42 x 1000|
|Day's range||3.28 - 3.40|
|52-week range||2.24 - 40.34|
|PE ratio (TTM)||N/A|
|Earnings date||6 Nov 2017 - 10 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||3.83|
Vertex (VRTX) received CHMP recommendation for label expansion of Orkambi in children aged 6 to 11 years with CF who have two copies of the F508del mutation.
Ophthotech (OPHT) reported better-than-expected third-quarter earnings and sales. The company continues to advance Zimura in several indications.
On a per-share basis, the New York-based company said it had profit of $5.25. The clinical-stage biotech focused on eye diseases posted revenue of $206.7 million in the period. The company's shares closed ...
Ophthotech Corporation today announced financial and operating results for the third quarter ended September 30, 2017 and provided a business update.
Ophthotech Corporation today announced that it will report its third quarter 2017 financial and operating results on Wednesday, November 8, 2017. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m.